Cancer Breakthroughs. Realized. We help transform groundbreaking cancer-related research and innovation in Ontario into viable commercial opportunities that benefit patients, researchers, investors and Ontario's economy.
Anil Amlani expands FACIT’s oncology expertise in medical device sector
Anil Amlani joins FACIT with strong executive and transactional experience, broadening the available expertise to provide critical senior management and leadership to create and nurture FACIT start-ups in Ontario.
First Patient Treated in Turnstone's Lung Cancer Trial Combining Novel Viral Cancer Therapy with Approved Checkpoint Inhibitor
Combination of Turnstone's oncolytic viral immunotherapy with checkpoint inhibitors showed promising results in preclinical testing.
Turnstone announced that treatment has been initiated on the first patient in the company's Phase I/II clinical trial combining its novel oncolytic viral immunotherapy agent, MG1-MAGEA3, with pembrolizumab, an approved anti-PD-1 antibody.
Seed financing of CAD$3.0M positions first-in-class WDR5 cancer therapy for clinical development.
Seed funding from FACIT enables Propellon to accelerate the nomination of a candidate drug and position the Company for financing and/or entering a strategic partnership for clinical trials in patients with haematological cancers.
New evergreen fund to help Ontario discoveries reach seed-stage funding faster.
FACIT announces the launch of The Prospects Oncology Fund, designed to advance early-stage Ontario cancer discoveries by supporting the proof-of-concept studies needed to attract seed-stage investment.
Financing leverages and strengthens Ontario’s next-generation radiotherapeutics expertise, products.
FACIT and OICR report that Fusion Pharmaceuticals Inc. has closed a US$25M Series A financing, with Johnson & Johnson Innovation – JJDC, Inc. as the lead investor. Additionally, new investors include venture groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as well as founding investor FACIT.
The new collaboration provides Celgene with an option to acquire all Triphase Accelerator’s assets relating to TRPH 222 (CD22-4AP), an antibody-drug conjugate in development for lymphoma.
Triphase Accelerator Corporation announced a new strategic collaboration with Celgene Corporation, that provides Celgene with an option to acquire all Triphase Accelerator’s assets relating to TRPH 222 (CD22-4AP), an antibody-drug conjugate in development for lymphoma.
Marizomib is a novel brain-penetrant proteasome inhibitor in development for patients with glioblastoma and relapsed and/or refractory multiple myeloma
Triphase Accelerator Announces that Celgene Corporation has acquired the company's assets related to its proteasome inhibitor, marizomib, which is in development for glioblastoma and relapsed and/or refractory multiple myeloma.
OrbiMed, Versant-led round continues commercialization success for Turnstone’s cancer therapies
FACIT-created Turnstone Biologics raises USD $41M, one of the largest Series B rounds for a Canadian biotech, attracting blue-chip healthcare investors to accelerate commercialization of proprietary oncolytic viral immunotherapies.
Catalent Biologics and Triphase Accelerator Corporation Announce License Agreement to Advance SMARTag™ ADC to Clinic
Triphase will obtain worldwide rights to further develop Catalent's proprietary CD22-4AP Antibody-Drug Conjugate (ADC), which has been developed by Catalent’s wholly owned subsidiary, Redwood Bioscience, Inc., using its SMARTag™ technology platform.
FACIT forms biotechnology company for OICR-discovered first-in-class epigenetic modifiers
The creation of Propellon to manage the development and commercialization of a portfolio of first-in-class epigenetic therapeutics, WDR5 inhibitors, enables important development activities including attracting private sector investment and industry partnerships.